Nanoformulation Containing an Exosome-Derived Monoclonal Antibody
and a Drug-Binding Ligand Targeting the Transferrin Receptor (TfR) for Glioblastoma
Versandkostenfrei!
Versandfertig in 6-10 Tagen
49,99 €
inkl. MwSt.
PAYBACK Punkte
25 °P sammeln!
The book introduces an innovative approach to overcoming therapeutic resistance in one of the most aggressive brain cancers. This book explores how nanotechnology, exosome engineering, and targeted delivery systems can be combined to improve drug transport across the blood-brain barrier. It emphasizes the role of exosome-derived monoclonal antibodies and TfR-targeting ligands in enhancing specificity, stability, and therapeutic efficacy for glioblastoma treatment. The text integrates concepts from molecular biology, oncology, pharmacology, and bioengineering, providing a multidisciplinary pers...
The book introduces an innovative approach to overcoming therapeutic resistance in one of the most aggressive brain cancers. This book explores how nanotechnology, exosome engineering, and targeted delivery systems can be combined to improve drug transport across the blood-brain barrier. It emphasizes the role of exosome-derived monoclonal antibodies and TfR-targeting ligands in enhancing specificity, stability, and therapeutic efficacy for glioblastoma treatment. The text integrates concepts from molecular biology, oncology, pharmacology, and bioengineering, providing a multidisciplinary perspective on translational applications. With a focus on precision medicine, the book outlines preclinical insights, potential clinical strategies, and future directions for nanoformulated therapies that bridge diagnostics and therapeutics. It serves as a valuable resource for researchers, clinicians, and graduate students seeking to advance glioblastoma treatment through cutting-edge nanomedicine platforms.
Andere Kunden interessierten sich für
